Plasma levels of high-sensitive C-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques

Journal of Internal Medicine

Volumn 275, Issue 2, 2014, Pages 127-133

  Grufman, H ^a,b   Goncalves I ^a,b   Edsfeldt, A ^a   Nitulescu, M ^a   Persson, A ^a,b   Nilsson, M ^a,b   Nilsson, J ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c STELLENBOSCH INSTITUTE FOR ADVANCED STUDY   (South Africa)

Author keywords

Atherosclerotic plaque; C reactive protein; Cytokines; Macrophage

Indexed keywords

ALPHA ACTIN; C REACTIVE PROTEIN; CD68 ANTIGEN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DISEASE COURSE; ENDARTERECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INFLAMMATION; LEUKOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ATHEROSCLEROTIC PLAQUE; C-REACTIVE PROTEIN; CYTOKINES; MACROPHAGE;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID STENOSIS; CHEMOKINE CCL2; CYTOKINES; FEMALE; HUMANS; IMMUNOASSAY; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892502602     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12133     Document Type: Article

References (23)

1. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013; 56: 131-42.
2. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, asprin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
3. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
5. Koenig W, Sund M, Frohlich M et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
6. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.
7. Kaptoge S, Di Angelantonio E, Pennells L et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-20.
8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
9. Yaron G, Brill A, Dashevsky O et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 2006; 134: 426-31.
10. Grad E, Danenberg HD. C-reactive protein and atherothrombosis: Cause or effect? Blood Rev 2013; 27: 23-9.
11. -/- mice. Atherosclerosis 2008; 196: 248-55.
12. Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Bjorkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 2007; 104: 13768-73.
13. Paul A, Ko KW, Li L et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647-55.
14. Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Curr Opin Lipidol 2009; 20: 393-401.
15. Baldassarre D, De Jong A, Amato M et al. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann Med 2008; 40: 21-44.
16. Bamberg F, Truong QA, Koenig W et al. Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography. Int J Cardiovasc Imaging 2012; 28: 183-92.
17. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 2137-42.
18. Ohta H, Wada H, Niwa T et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005; 180: 11-7.
19. Dirksen MT, van der Wal AC, van den Berg FM, van der Loos CM, Becker AE. Distribution of inflammatory cells in atherosclerotic plaques relates to the direction of flow. Circulation 1998; 98: 2000-3.
20. Yilmaz A, Lipfert B, Cicha I et al. Accumulation of immune cells and high expression of chemokines/chemokine receptors in the upstream shoulder of atherosclerotic carotid plaques. Exp Mol Pathol 2007; 82: 245-55.
21. Fagerberg B, Ryndel M, Kjelldahl J et al. Differences in lesion severity and cellular composition between in vivo assessed upstream and downstream sides of human symptomatic carotid atherosclerotic plaques. J Vasc Res 2010; 47: 221-30.
22. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-81.
23. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67.